Biomea Fusion, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Biomea Fusion, Inc. stock issued during period, value, new issues for the quarter ending 2025-06-30 was $1.65M.
- Biomea Fusion, Inc. stock issued during period, value, new issues for the quarter ending 2025-03-31 was $3.26M.
- Biomea Fusion, Inc. stock issued during period, value, new issues for the quarter ending 2023-06-30 was $161.80M.
- Biomea Fusion, Inc. stock issued during period, value, new issues for the quarter ending 2020-06-30 was $9.49M.
- Biomea Fusion, Inc. stock issued during period, value, new issues for fiscal 2020 was $10.19M, a 607.78% increase from fiscal 2019.
- Biomea Fusion, Inc. stock issued during period, value, new issues for fiscal 2019 was $1.44M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2025-06-30 | $1.65M 10-Q · filed 2026-08-05 | |
| 2025-03-31 | $3.26M 10-Q · filed 2026-08-05 | |
| 2023-06-30 | $161.80M 10-Q · filed 2023-10-30 | |
| 2020-12-31 | $10.19M 10-K · filed 2023-03-28 | |
| 2020-06-30 | $9.49M 10-Q · filed 2021-11-03 | |
| 2020-03-31 | $50.00K 10-Q · filed 2021-11-03 | |
| 2019-12-31 | $1.44M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |